Concord Biotech Hits Upper Circuit, Stages Sharp Rebound from 52-Week Low

witnessed extreme volatility on 25 Feb 2026, with the stock surging up to 20% intraday to hit the upper circuit at ₹1,291.30. The sharp spike came after the counter rebounded strongly from a fresh 52-week low of ₹1,068 recorded yesterday — its lowest level since 6 Oct 2023. The swift recovery reflects aggressive buying interest supported by elevated trading volumes. Concord Biotech is a globally recognized fermentation-based API player, particularly strong in immunosuppressants and oncology. The company has also expanded its formulations footprint across regulated markets such as the US, Europe, and Japan, alongside multiple emerging markets since 2016. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.